Medicine:Fish oil (medical use)

From HandWiki
Fish oil
Clinical data
Trade namesOmegaven
Other namesFish oil triglycerides
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Dependence
liability
Intravenous
Drug classIntravenous nutritional products
ATC code
  • None
Legal status
Legal status

Fish oil, sold under the brand name Omegaven, is a fatty acid emulsion.[2] It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome.[2] It is rich in omega-3 fatty acids.[2]

Fish oil triglycerides was approved for use in the United States in July 2018,[3] and is available to people on the US market by prescription effective November 2018.[4]

In 2021, it was the 283rd most commonly prescribed medication in the United States, with more than 700,000 prescriptions.[5][6]

Research

It has gained popularity in children in preference to the more commonly used intralipid after case reports that it reduced the risk of liver damage.[7]

A 2007, study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastroschisis, and intestinal atresia.[8]

A clinical trial exploring the use of fish oil as an adjunct to parenteral nutrition in surgical intensive care units at National Taiwan University Hospital completed in March 2007.[9]

Although the use of fish oil triglycerides in children in the United States is experimental, the use of it in adults in Europe is less controversial.[10] In European studies, fish oil triglycerides have been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[11] Fish oil triglycerides have also been associated with reduced mortality and antibiotic use during hospital stays.[12]

References

  1. "Fat emulsion Use During Pregnancy". 4 May 2020. https://www.drugs.com/pregnancy/fat-emulsion.html. 
  2. 2.0 2.1 2.2 2.3 "Omegaven- fish oil injection, emulsion". 6 August 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9d0b24-e139-48bf-ab2d-536fb59cf8e0. 
  3. "Drug Approval Package: Omegaven (fish oil triglycerides)". 24 August 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210589Orig1s000TOC.cfm. 
  4. Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded Access Use". https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm368740.htm. 
  5. "The Top 300 of 2021". https://clincalc.com/DrugStats/Top300Drugs.aspx. 
  6. "Fish Oil - Drug Usage Statistics". https://clincalc.com/DrugStats/Drugs/FishOil. 
  7. "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics 118 (1): e197–201. 2006. doi:10.1542/peds.2005-2662. PMID 16818533. 
  8. "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of Perinatology 27 (5): 284–90. 2007. doi:10.1038/sj.jp.7211686. PMID 17344923. 
  9. Clinical trial number NCT00172198 for "Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU." at ClinicalTrials.gov
  10. A Doctor's Push For Drug Pits Him Against Its Maker at The Wall Street Journal
  11. "n-3 fatty acids in psoriasis". Br. J. Nutr.. 87 Suppl 1: S77–82. 2002. doi:10.1079/bjn2001459. PMID 11895157. 
  12. "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. 2006. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909. 

External links